Telomir Pharmaceuticals, Inc

PRESS RELEASE

published on 06/05/2025 at 14:30, 11 months 16 days ago

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Telomir-1 treatment shows promising results in reversing aging hallmarks in a rare genetic disorder. Findings include restored gene control, extended telomere length, muscle and weight recovery, reduced oxidative stress, and 100% survival

Preclinical Data Genetic Disorder Telomir-1 Age-Reversal Telomere Length
BRIEF

published on 06/02/2025 at 14:35, 11 months 19 days ago

Telomir Pharmaceuticals to Advance Age-Reversal Research at BIO 2025

Rare Diseases IND Submission Telomir-1 Age-Reversal Preclinical Success
BRIEF

published on 06/02/2025 at 14:35, 11 months 19 days ago

Telomir Pharmaceuticals fera progresser la recherche sur l'inversion du vieillissement au BIO 2025

Maladies Rares Telomir-1 Inversion Du Vieillissement Soumission IND Succès Préclinique
PRESS RELEASE

published on 06/02/2025 at 14:30, 11 months 19 days ago

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
Telomir Pharmaceuticals, Inc. to meet prospective partners at BIO International Convention 2025 to accelerate IND submission for Telomir-1, preparing for human dosing in 2026

BIO International Convention IND Submission Telomir-1 Telomir Pharmaceuticals Human Dosing
BRIEF

published on 05/29/2025 at 14:35, 11 months 23 days ago

Telomir-1 Shows Promise in Restoring Vision in AMD Animal Model

Telomir-1 Retina Regeneration AMD Model Zebrafish Study Vision Restoration
BRIEF

published on 05/29/2025 at 14:35, 11 months 23 days ago

Telomir-1 s'avère prometteur pour restaurer la vision dans un modèle animal de DMLA

Telomir-1 Régénération De La Rétine Modèle AMD Étude Sur Le Poisson Zèbre Restauration De La Vision
PRESS RELEASE

published on 05/29/2025 at 14:30, 11 months 23 days ago

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints
Telomir Pharmaceuticals reports positive preclinical results for oral drug Telomir-1 in age-related macular degeneration (AMD) model, showing vision restoration, retinal regeneration, and reduced oxidative stress

Preclinical Results Telomir-1 Telomir Pharmaceuticals Age-related Macular Degeneration Vision Restoration
BRIEF

published on 05/15/2025 at 14:05, 1 year ago

Telomir Pharmaceuticals Introduces Telomir-Ag2, Targeting Drug-Resistant Infections

Antimicrobial Resistance Healthcare Market Telomir Pharmaceuticals Silver(II) Stabilization Drug-resistant Pathogens
BRIEF

published on 05/15/2025 at 14:05, 1 year ago

Telomir Pharmaceuticals présente Telomir-Ag2, un médicament ciblant les infections résistantes aux médicaments

Résistance Aux Antimicrobiens Telomir Pharmaceuticals Stabilisation À L'argent (II) Agents Pathogènes Résistants Aux Médicaments Marché De La Santé
PRESS RELEASE

published on 05/15/2025 at 14:00, 1 year ago

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity
Telomir Pharmaceuticals, Inc. announces Telomir-Ag2, a novel drug candidate addressing antimicrobial resistance with broad-spectrum activity, particularly against drug-resistant pathogens

Antimicrobial Resistance Drug Candidate Telomir Pharmaceuticals Inc. Telomir-Ag2 Silver(II) Complex

Published on 05/22/2026 at 00:45, 1 hour 9 minutes ago

Credissential Announces Private Placement
Published on 05/21/2026 at 23:00, 2 hours 54 minutes ago

Silver Wolf Adopts Semi-Annual Financial Reporting
Published on 05/21/2026 at 23:00, 2 hours 54 minutes ago

Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
Published on 05/21/2026 at 23:00, 2 hours 54 minutes ago

Revival Gold Announces Adoption of Shareholder Rights Plan and Corporate Update
Published on 05/21/2026 at 22:15, 3 hours 39 minutes ago

Linear Announces Acquisition, Share Consolidation and Private Placement

View all ACCESSWIRE

Published on 05/21/2026 at 21:45, 4 hours 8 minutes ago

Rendeavour becomes the African Continental Free Trade Area's inaugural implementation partner for African industrialisation and trade infrastructure
Published on 05/21/2026 at 20:10, 5 hours 43 minutes ago

Ernst Russ AG Divests MV 'EF Emira' and Raises Full-Year 2026 Guidance
Published on 05/21/2026 at 20:05, 5 hours 48 minutes ago

EQS-Adhoc: Ernst Russ AG: Upward revision of the guidance for the financial year 2026
Published on 05/21/2026 at 20:00, 5 hours 53 minutes ago

VINFAST INTRODUCES THE NEW-GENERATION VF 8, FEATURING COMPREHENSIVE ENHANCEMENTS
Published on 05/21/2026 at 18:26, 7 hours 27 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

View all EQS

Published on 05/21/2026 at 17:50, 8 hours 4 minutes ago

CDA - H1 results 2025 2026
Published on 05/21/2026 at 17:45, 8 hours 9 minutes ago

CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 05/21/2026 at 17:45, 8 hours 9 minutes ago

CEGEDIM: DECLARATION D’ACTIONS ET DE DROITS DE VOTE
Published on 05/21/2026 at 17:45, 8 hours 9 minutes ago

CDA - Résultats de 1er semestre 2025 2026
Published on 05/21/2026 at 16:35, 9 hours 18 minutes ago

260521 BENETEAU Déclaration du nombre d'actions et de droits de vote au 30-04-2026

View all LES ECHOS COMFI WIRE

News